Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GREAT: Influence of Residual Beta Cell Function on Hypoglycaemia Risk and Treatment Response in T2D
NCT02506296Completed
- Sponsor
- Royal Devon University Healthcare NHS Foundation Trust
- Start
- Oct 2014
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vildagliptin in type 2 diabetes mellitus (T2DM), sponsored by Royal Devon University Healthcare NHS Foundation Trust. Primary endpoints: Difference in glucose variability and Difference in response to a standard DPPIV therapy at 180 minutes. Started Oct 2014; status: completed.
02
Drugs
vildagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02506296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506296.